The Use of Immunotherapy In RCC: Where are we Now?

Access Activity

Overview / Abstract:

Target Audience
The target audiences for this education are urologists, oncologists, PAs, nurse practitioners, and other health care professionals involved in the management of patients with RCC.

Program Overview
Learn the latest clinical information related to the treatment of renal cell carcinoma (RCC) with immune checkpoint inhibitors with three experts through case studies.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Review immunotherapies and therapy combinations for the management of both malignant RCC and adjuvant treatment
Select an appropriate immunotherapeutic agent for patients with RCC based on individual patient characteristics and needs
Monitor RCC patients receiving immunotherapy for adverse events
Manage adverse events in a timely fashion in RCC patients receiving immunotherapy

Expiration

Mar 16, 2024

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1.0

Accreditation

ACCME, ACPE, ANCC

Presenters / Authors / Faculty

Pedro Barata, MD, MSc
Tian Zhang, MD, MHS
Kiran Virdee, BSN, RN

Sponsors / Supporters / Grant Providers

Merck

Keywords / Search Terms

Relias LLC Relias, Free CME, renal cell carcinoma (RCC) Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map